We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+2.77%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$389M
AUM Growth
-$2.47M
(-0.63%)
Cap. Flow
-$8.25M
Cap. Flow
% of AUM
-2.12%
Top 10 Holdings %
Top 10 Hldgs %
92.75%
Holding
15
New
1
Increased
5
Reduced
8
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$8.35M |
| 2 |
Elanco Animal Health
ELAN
|
+$7.03M |
| 3 |
Orthofix Medical
OFIX
|
+$541K |
| 4 |
Gilead Sciences
GILD
|
+$511K |
| 5 |
SHPG
Shire pic
SHPG
|
+$318K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$8.15M |
| 2 |
AVNS
Avanos Medical
AVNS
|
+$6.97M |
| 3 |
Amgen
AMGN
|
+$6.17M |
| 4 |
JNP
Juniper Pharmaceuticals, Inc. Common Stock
JNP
|
+$2.68M |
| 5 |
Enanta Pharmaceuticals
ENTA
|
+$786K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$25.8B
| $62.2M | 15.97% |
486,103
-65,916
| -12% | -$8.15M |
|
|
2
McKesson
MCK
$100B
| $51.5M | 13.24% |
388,268
+64,025
| +20% | +$8.35M |
|
|
3
Amgen
AMGN
$208B
| $44.1M | 11.33% |
212,655
-31,331
| -13% | -$6.17M |
|
|
4
Enanta Pharmaceuticals
ENTA
$366M
| $43.7M | 11.23% |
511,186
-7,849
| -2% | -$786K |
|
|
5
Gilead Sciences
GILD
$162B
| $41.7M | 10.71% |
539,836
+6,767
| +1% | +$511K |
|
6
Merck
MRK
$322B
| $36.2M | 9.31% |
535,432
-4,737
| -0.9% | -$302K |
|
|
SHPG
7
DELISTED
Shire pic
SHPG
| $26.2M | 6.74% |
144,596
+1,838
| +1% | +$318K |
|
|
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $20.1M | 5.16% |
148,748
-102
| -0.1% | -$14.1K |
|
|
9
Orthofix Medical
OFIX
$477M
| $17.9M | 4.6% |
309,708
+9,659
| +3% | +$541K |
|
|
IVC
10
DELISTED
Invacare Corporation
IVC
| $15.6M | 4.02% |
1,075,263
+13,648
| +1% | +$226K |
|
|
11
Elanco Animal Health
ELAN
$13.2B
| $6.98M | 1.79% |
+200,000
| New | +$7.03M |
|
|
AVNS
12
DELISTED
Avanos Medical
AVNS
| $5.09M | 1.31% |
74,258
-108,244
| -59% | -$6.97M |
|
|
STRR
13
DELISTED
Star Equity Holdings
STRR
| $499K | 0.13% |
6,652
-5
| -0.1% | -$417 |
|
|
JNP
14
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| – | – |
-308,478
| Closed | -$2.68M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q3 2018 Portfolio in Review
As of Q3 2018, Krensavage Asset Management held 15 positions worth $389M, down 0.63% from $392M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Krensavage Asset Management's Q3 2018 filing shows 1 new, 5 increased, 8 reduced and 1 closed positions. Its largest new stake was Elanco Animal Health: 200,000 shares worth $6.98M. The largest sale was United Therapeutics, an estimated $8.15M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier.
- Krensavage Asset Management's largest Q3 2018 buy was Elanco Animal Health: 200,000 shares worth $6.98M.
- Krensavage Asset Management added most to McKesson in Q3 2018, an estimated $8.35M increase.
- Krensavage Asset Management's biggest Q3 2018 reduction was United Therapeutics, cutting an estimated $8.15M.
- Krensavage Asset Management fully exited Juniper Pharmaceuticals, Inc. Common Stock in Q3 2018, selling an estimated $2.68M.
- Krensavage Asset Management's ten largest holdings make up 93% of its $389M portfolio in Q3 2018.
- Krensavage Asset Management opened 1 new position and closed 1 in Q3 2018.
- Krensavage Asset Management's portfolio value fell 0.63% quarter-over-quarter to $389M.
Based on Krensavage Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.